Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy
Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients wi...
Gespeichert in:
| Veröffentlicht in: | Hepatitis monthly 2012-11, Vol.12 (11), p.e7292-e7292 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e7292 |
|---|---|
| container_issue | 11 |
| container_start_page | e7292 |
| container_title | Hepatitis monthly |
| container_volume | 12 |
| creator | Caviglia, Gian Paolo Abate, Maria Lorena Manzini, Paola Danielle, Franca Ciancio, Alessia Rosso, Chiara Olivero, Antonella Pellicano, Rinaldo Touscoz, Giovanni Antonio Smedile, Antonina Rizzetto, Mario |
| description | Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear.
The Aim of this study was to assess OBI prevalence and its potential implications on treatment outcome in a cohort of patients with CHC underwent standard antiviral therapy.
Baseline serum samples from 137 HBsAg-negative CHC patients treated with pegylated-interferon and ribavirin (73 Responders/74 Non Responders),were retrospectively analyzed for HBV status.
Seventy-three patients (53.3%) showed markers of previous exposure to HBV. HBV DNA was detected in 2 of 137 serum samples (1.5%), both carrying HBV antibodies. Liver biopsies and post-therapy sera were available for 35 patients (12 Responders/23 Non Responders). HBV DNA sequences were found in 13 of 35 specimens (37.1%), all of patients with HBV DNA negativity in basal and post-therapy serum samples. Among OBI-positive patients, 5 (38.5%) carried serological markers of HBV infection. Regarding therapy outcome, in the OBI-positive group there were 5 of 13 (38.5%) sustained virological responders (SVR) compared to 7 of 22 (31.8%) in the OBI-negative one.
Despite the high prevalence rate of liver HBV DNA in patients with CHC, SVR was not affected by occult HBV infection. |
| doi_str_mv | 10.5812/hepatmon.7292 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273352389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-ce8493e54fc45d77de34abadee72b69c4aed7cc9add2b29c09475fc2b937fbc23</originalsourceid><addsrcrecordid>eNpdkU1rFTEUhoMotlaXbiXgxs3UfDaTjaAXv6DQjYK7kDlzxkmZm1yTTKX_3lzvbamucuA8eXgPLyEvOTvXPRdvZ9z5uk3x3AgrHpFTbqTupGL94-PMlfxxQp6Vcs2Y7pkRT8mJkJIxZc0pma4A1qXSv5pQQ6Ef6E3Ia6EhTgg1pNgmul9irIX-DnWmMOcUAzz4tKE1o684HgAfa2gWv9A6Y_a72-fkyeSXgi-O7xn5_unjt82X7vLq89fN-8sOFNe1A-yVlajVBEqPxowolR_8iGjEcGFBeRwNgPXjKAZhgVll9ARisNJMAwh5Rt4dvLt12OIILXNL4XY5bH2-dckH9-8mhtn9TDdOamnZBW-CN0dBTr9WLNVtQwFcFh8xrcVxYaTUQva2oa__Q6_TmmM7z3HJNdetkL5R3YGCnErJON2H4cztG3R3Dbp9g41_9fCCe_quMvkHedKcqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315152928</pqid></control><display><type>article</type><title>Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Caviglia, Gian Paolo ; Abate, Maria Lorena ; Manzini, Paola ; Danielle, Franca ; Ciancio, Alessia ; Rosso, Chiara ; Olivero, Antonella ; Pellicano, Rinaldo ; Touscoz, Giovanni Antonio ; Smedile, Antonina ; Rizzetto, Mario</creator><creatorcontrib>Caviglia, Gian Paolo ; Abate, Maria Lorena ; Manzini, Paola ; Danielle, Franca ; Ciancio, Alessia ; Rosso, Chiara ; Olivero, Antonella ; Pellicano, Rinaldo ; Touscoz, Giovanni Antonio ; Smedile, Antonina ; Rizzetto, Mario</creatorcontrib><description>Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear.
The Aim of this study was to assess OBI prevalence and its potential implications on treatment outcome in a cohort of patients with CHC underwent standard antiviral therapy.
Baseline serum samples from 137 HBsAg-negative CHC patients treated with pegylated-interferon and ribavirin (73 Responders/74 Non Responders),were retrospectively analyzed for HBV status.
Seventy-three patients (53.3%) showed markers of previous exposure to HBV. HBV DNA was detected in 2 of 137 serum samples (1.5%), both carrying HBV antibodies. Liver biopsies and post-therapy sera were available for 35 patients (12 Responders/23 Non Responders). HBV DNA sequences were found in 13 of 35 specimens (37.1%), all of patients with HBV DNA negativity in basal and post-therapy serum samples. Among OBI-positive patients, 5 (38.5%) carried serological markers of HBV infection. Regarding therapy outcome, in the OBI-positive group there were 5 of 13 (38.5%) sustained virological responders (SVR) compared to 7 of 22 (31.8%) in the OBI-negative one.
Despite the high prevalence rate of liver HBV DNA in patients with CHC, SVR was not affected by occult HBV infection.</description><identifier>ISSN: 1735-143X</identifier><identifier>EISSN: 1735-3408</identifier><identifier>DOI: 10.5812/hepatmon.7292</identifier><identifier>PMID: 23300497</identifier><language>eng</language><publisher>Iran: Tehran Hepatitis Center</publisher><ispartof>Hepatitis monthly, 2012-11, Vol.12 (11), p.e7292-e7292</ispartof><rights>Copyright Tehran Hepatitis Center 2012</rights><rights>Copyright © 2012, Kowsar Corp. 2012</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-ce8493e54fc45d77de34abadee72b69c4aed7cc9add2b29c09475fc2b937fbc23</citedby><cites>FETCH-LOGICAL-c415t-ce8493e54fc45d77de34abadee72b69c4aed7cc9add2b29c09475fc2b937fbc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539061/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539061/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23300497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caviglia, Gian Paolo</creatorcontrib><creatorcontrib>Abate, Maria Lorena</creatorcontrib><creatorcontrib>Manzini, Paola</creatorcontrib><creatorcontrib>Danielle, Franca</creatorcontrib><creatorcontrib>Ciancio, Alessia</creatorcontrib><creatorcontrib>Rosso, Chiara</creatorcontrib><creatorcontrib>Olivero, Antonella</creatorcontrib><creatorcontrib>Pellicano, Rinaldo</creatorcontrib><creatorcontrib>Touscoz, Giovanni Antonio</creatorcontrib><creatorcontrib>Smedile, Antonina</creatorcontrib><creatorcontrib>Rizzetto, Mario</creatorcontrib><title>Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy</title><title>Hepatitis monthly</title><addtitle>Hepat Mon</addtitle><description>Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear.
The Aim of this study was to assess OBI prevalence and its potential implications on treatment outcome in a cohort of patients with CHC underwent standard antiviral therapy.
Baseline serum samples from 137 HBsAg-negative CHC patients treated with pegylated-interferon and ribavirin (73 Responders/74 Non Responders),were retrospectively analyzed for HBV status.
Seventy-three patients (53.3%) showed markers of previous exposure to HBV. HBV DNA was detected in 2 of 137 serum samples (1.5%), both carrying HBV antibodies. Liver biopsies and post-therapy sera were available for 35 patients (12 Responders/23 Non Responders). HBV DNA sequences were found in 13 of 35 specimens (37.1%), all of patients with HBV DNA negativity in basal and post-therapy serum samples. Among OBI-positive patients, 5 (38.5%) carried serological markers of HBV infection. Regarding therapy outcome, in the OBI-positive group there were 5 of 13 (38.5%) sustained virological responders (SVR) compared to 7 of 22 (31.8%) in the OBI-negative one.
Despite the high prevalence rate of liver HBV DNA in patients with CHC, SVR was not affected by occult HBV infection.</description><issn>1735-143X</issn><issn>1735-3408</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1rFTEUhoMotlaXbiXgxs3UfDaTjaAXv6DQjYK7kDlzxkmZm1yTTKX_3lzvbamucuA8eXgPLyEvOTvXPRdvZ9z5uk3x3AgrHpFTbqTupGL94-PMlfxxQp6Vcs2Y7pkRT8mJkJIxZc0pma4A1qXSv5pQQ6Ef6E3Ia6EhTgg1pNgmul9irIX-DnWmMOcUAzz4tKE1o684HgAfa2gWv9A6Y_a72-fkyeSXgi-O7xn5_unjt82X7vLq89fN-8sOFNe1A-yVlajVBEqPxowolR_8iGjEcGFBeRwNgPXjKAZhgVll9ARisNJMAwh5Rt4dvLt12OIILXNL4XY5bH2-dckH9-8mhtn9TDdOamnZBW-CN0dBTr9WLNVtQwFcFh8xrcVxYaTUQva2oa__Q6_TmmM7z3HJNdetkL5R3YGCnErJON2H4cztG3R3Dbp9g41_9fCCe_quMvkHedKcqg</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Caviglia, Gian Paolo</creator><creator>Abate, Maria Lorena</creator><creator>Manzini, Paola</creator><creator>Danielle, Franca</creator><creator>Ciancio, Alessia</creator><creator>Rosso, Chiara</creator><creator>Olivero, Antonella</creator><creator>Pellicano, Rinaldo</creator><creator>Touscoz, Giovanni Antonio</creator><creator>Smedile, Antonina</creator><creator>Rizzetto, Mario</creator><general>Tehran Hepatitis Center</general><general>Kowsar</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121101</creationdate><title>Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy</title><author>Caviglia, Gian Paolo ; Abate, Maria Lorena ; Manzini, Paola ; Danielle, Franca ; Ciancio, Alessia ; Rosso, Chiara ; Olivero, Antonella ; Pellicano, Rinaldo ; Touscoz, Giovanni Antonio ; Smedile, Antonina ; Rizzetto, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-ce8493e54fc45d77de34abadee72b69c4aed7cc9add2b29c09475fc2b937fbc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Caviglia, Gian Paolo</creatorcontrib><creatorcontrib>Abate, Maria Lorena</creatorcontrib><creatorcontrib>Manzini, Paola</creatorcontrib><creatorcontrib>Danielle, Franca</creatorcontrib><creatorcontrib>Ciancio, Alessia</creatorcontrib><creatorcontrib>Rosso, Chiara</creatorcontrib><creatorcontrib>Olivero, Antonella</creatorcontrib><creatorcontrib>Pellicano, Rinaldo</creatorcontrib><creatorcontrib>Touscoz, Giovanni Antonio</creatorcontrib><creatorcontrib>Smedile, Antonina</creatorcontrib><creatorcontrib>Rizzetto, Mario</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatitis monthly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caviglia, Gian Paolo</au><au>Abate, Maria Lorena</au><au>Manzini, Paola</au><au>Danielle, Franca</au><au>Ciancio, Alessia</au><au>Rosso, Chiara</au><au>Olivero, Antonella</au><au>Pellicano, Rinaldo</au><au>Touscoz, Giovanni Antonio</au><au>Smedile, Antonina</au><au>Rizzetto, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy</atitle><jtitle>Hepatitis monthly</jtitle><addtitle>Hepat Mon</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>12</volume><issue>11</issue><spage>e7292</spage><epage>e7292</epage><pages>e7292-e7292</pages><issn>1735-143X</issn><eissn>1735-3408</eissn><abstract>Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear.
The Aim of this study was to assess OBI prevalence and its potential implications on treatment outcome in a cohort of patients with CHC underwent standard antiviral therapy.
Baseline serum samples from 137 HBsAg-negative CHC patients treated with pegylated-interferon and ribavirin (73 Responders/74 Non Responders),were retrospectively analyzed for HBV status.
Seventy-three patients (53.3%) showed markers of previous exposure to HBV. HBV DNA was detected in 2 of 137 serum samples (1.5%), both carrying HBV antibodies. Liver biopsies and post-therapy sera were available for 35 patients (12 Responders/23 Non Responders). HBV DNA sequences were found in 13 of 35 specimens (37.1%), all of patients with HBV DNA negativity in basal and post-therapy serum samples. Among OBI-positive patients, 5 (38.5%) carried serological markers of HBV infection. Regarding therapy outcome, in the OBI-positive group there were 5 of 13 (38.5%) sustained virological responders (SVR) compared to 7 of 22 (31.8%) in the OBI-negative one.
Despite the high prevalence rate of liver HBV DNA in patients with CHC, SVR was not affected by occult HBV infection.</abstract><cop>Iran</cop><pub>Tehran Hepatitis Center</pub><pmid>23300497</pmid><doi>10.5812/hepatmon.7292</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1735-143X |
| ispartof | Hepatitis monthly, 2012-11, Vol.12 (11), p.e7292-e7292 |
| issn | 1735-143X 1735-3408 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539061 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| title | Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T11%3A42%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Occult%20hepatitis%20B%20virus%20infection%20in%20patients%20with%20chronic%20hepatitis%20C%20treated%20with%20antiviral%20therapy&rft.jtitle=Hepatitis%20monthly&rft.au=Caviglia,%20Gian%20Paolo&rft.date=2012-11-01&rft.volume=12&rft.issue=11&rft.spage=e7292&rft.epage=e7292&rft.pages=e7292-e7292&rft.issn=1735-143X&rft.eissn=1735-3408&rft_id=info:doi/10.5812/hepatmon.7292&rft_dat=%3Cproquest_pubme%3E1273352389%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1315152928&rft_id=info:pmid/23300497&rfr_iscdi=true |